Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 1.01, 9.01 · 8-K

DSS, Inc.

DSSNYSE_AMERICANEQUITYCurrent

Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement with Alset, Inc. On June 23, 2026, DSS, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Alset, Inc.…

Filed Jun 25, 2026Accepted Jun 25, 2026, 4:05 PM EDTCIK 771999Accession 0001493152-26-030115
Share

Company context

DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our,” or the “Company”) is a multi-segment operating company focused on packaging, biotechnology, financial services, and investment platform businesses. The Company operates through four principal business segments: Product Packaging, Biotechnology, Commercial Lending, and Securities and Investment Management. Through these segments, the Company seeks to develop and operate businesses across industries where management believes opportunities exist to create long-term shareholder value through operational growth, strategic partnerships, and the development or acquisition of complementary business platforms.

Current securities

Recent company filings

  1. Entry into a Material Definitive AgreementSep 21, 2026
  2. SCHEDULE 13D/A filingSep 8, 2026
  3. 424B5 filingSep 4, 2026
  4. 10-Q filingAug 14, 2026
  5. SCHEDULE 13D/A - filed by Chan Heng Fai Ambrose regarding DSS, INC.Jul 9, 2026

Disclosure sections

Items 1.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement with Alset, Inc. On June 23, 2026, DSS, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Alset, Inc. (“Alset”), a Texas corporation, pursuant to which Alset will loan the Company $1,000,000, in exchange for a convertible promissory note (the “Note”) and warrants to purchase 17,777,776 shares of the Company’s common stock pursuant to a warrant agreement (the “Warrant Agreement”). The Note, SPA and Warrant Agreement are collectively referred to herein as the “Transaction Documents”. The closing of the transactions contemplated by the Transaction Documents is subject to certain closing conditions, including approval of the Company’s stockholders. The Note will bear a simple interest at a rate of 3% per annum. Pursuant to the terms of the Note, Alset may convert any outstanding principal and accrued interest into shares of the Company’s common stock at a conversion price of $0.45 per share at any time prior to the maturity date, which is five (5) years from the date of issuance. The Warrant Agreement entitles Alset to purchase up to 17,777,776 shares of the Company’s common stock at an exercise price of $0.50 per share. The warrants expire on their third anniversary. Related Party Transaction The Company and Alset are related parties under common control of Chan Heng Fai, who serves as Chairman of the Company and is also Chairman and Chief Executive Officer of Alset. Chan Tung Moe, a director and Co-Chief Executive Officer of Alset, is also a director of the Company. Lim Sheng Hon Danny, a director and officer of Alset, is also a director of the Company. Certain independent directors of Alset also serve as directors of the Company. The Transaction Documents were approved by the Company’s Board of Directors and, where applicable, its Audit Committee. Any interested directors recused themselves from deliberations and voting regarding the Transaction Documents. The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Transaction Documents, copies of which are filed as Exhibits 10.1, 10.2 and 10.3 hereto and incorporated herein by reference.